Why Promising Women's Health Innovation Stalls.

A strong innovation can create market opportunity.

Women’s health is full of promising innovations addressing significant unmet needs. But clinical value, product innovation, and market demand don't automatically translate into commercial traction. This article explores the commercialization gaps that cause promising innovation to stall—and what companies need to build to move from market potential to repeatable growth.

By Julie Spence, Founder + Principal

The Innovation Isn't Usually the Problem

Some of the most difficult commercialization challenges begin with genuinely good products.

The clinical need is real. The innovation is differentiated. Early customers are enthusiastic. The market opportunity may be significant. And yet growth begins to slow, sales cycles stretch, adoption becomes inconsistent, or the company struggles to turn early traction into a repeatable commercial model.

I've seen this throughout my career in healthcare commercialization. When growth stalls, the instinct is often to increase activity: generate more leads, hire more salespeople, launch another campaign, enter another market, add another channel, or expand the product.

But more commercial activity doesn't necessarily solve a commercialization problem. Sometimes the issue sits further upstream.

The company hasn't made sufficiently clear choices about where to compete, who to serve, what value it creates, what evidence matters, how it should be positioned, or how customers will buy and adopt the solution.

And in women’s health, they can become particularly complicated because the person experiencing the problem, using the product, recommending the solution, paying for it, and making the purchasing decision may all be different people.

Innovation creates possibility. Commercialization creates a path for the market to adopt it.

The Market Is Too Broad

Women’s health is a category. It isn't a market strategy.

The addressable opportunity across fertility, maternity, menopause, reproductive health, maternal mental health, oncology, gynecologic health, and women’s primary care is enormous. That makes the sector attractive—but it can also make prioritization difficult.

A company may see legitimate opportunities across consumers, providers, employers, payers, health systems, fertility clinics, OB/GYN practices, or strategic partners.

The problem isn't that those opportunities aren't real. It's that a growing company rarely has the resources to pursue all of them equally well.

Commercialization requires making choices.

Which segment has the most urgent problem? Where is the strongest willingness to pay? Which buyer can act? Where does the evidence resonate most strongly? Which market provides the most credible path to adoption? Which opportunity creates leverage for the next?

A large TAM tells you the opportunity exists.

Market strategy tells you where to start.

Without that focus, resources spread across too many markets, messages, channels, and sales motions. The organization becomes busy without necessarily becoming more effective.

Scale requires expansion. But expansion without prioritization creates complexity before it creates growth.

The Buyer Isn't Clear

One of the most consequential questions in healthcare commercialization sounds deceptively simple:

Who is the customer?

In women’s health, there may not be one answer.

The patient may use the solution. A clinician may recommend it. An employer may sponsor it. A health plan may reimburse it. A health system may integrate it. A benefits consultant may influence the decision.

Each stakeholder sees the problem differently. And each needs a different reason to act.

A patient may value access, convenience, trust, or better outcomes. A clinician may care about evidence and workflow. An employer may evaluate utilization, productivity, retention, or healthcare costs. A payer may need evidence of clinical and economic value.

When those distinctions aren't clear, the value proposition becomes broad enough to speak to everyone—and specific enough to persuade no one.

Buyer strategy isn't simply identifying an audience.

It's understanding who experiences the value, who influences adoption, who makes the decision, who controls the budget, and what each needs to believe before the market can move.

A compelling value proposition begins with knowing whose decision you're trying to change.

The Value Hasn't Been Translated

A product can create meaningful clinical value without yet having a compelling commercial value proposition.

This distinction matters.

Companies naturally describe their products through what they have built: the technology, features, clinical model, methodology, data, or experience.

Buyers evaluate something different.

They want to understand what changes for them.

Does this improve outcomes? Reduce cost? Increase access? Solve a workforce problem? Improve productivity? Reduce administrative burden? Create capacity? Increase retention? Address a measurable gap in care?

The answer may also change by buyer.

The value proposition that motivates a consumer is unlikely to be identical to the one that moves an employer, payer, provider, or health system.

Commercialization requires translating the innovation into the clinical, operational, financial, and strategic value that matters to the people making the decision.

The market doesn't buy what you built. It buys the value your innovation creates.

The Evidence Doesn't Match the Buying Decision

Healthcare companies understand the importance of evidence.

But having evidence and having the right evidence for the buying decision are not necessarily the same thing.

Clinical outcomes may establish efficacy but leave an employer asking about utilization.

Patient satisfaction may demonstrate experience but leave a payer asking about cost.

Strong engagement may show demand but leave a health system asking about workflow, integration, and implementation.

A successful pilot may generate enthusiasm without demonstrating whether the result can be replicated across a larger population.

The question becomes less about whether the company has evidence and more about whether its evidence reduces the uncertainty standing between the buyer and a decision.

That means understanding what each buyer needs to believe—and deliberately building the proof required to support that belief.

Evidence becomes commercially valuable when it answers the questions preventing the buyer from saying yes.

The GTM Model Gets Ahead of Market Readiness

Growth-stage companies are under pressure to grow.

That pressure naturally drives investment in sales, marketing, partnerships, demand generation, and new channels.

But adding capacity to an unclear commercial model doesn't necessarily create growth.

It can amplify the uncertainty already inside it.

If the ICP isn't clear, demand generation targets the wrong accounts. If positioning isn't differentiated, sales has difficulty creating urgency. If the value proposition doesn't reflect buyer priorities, conversations stall. If evidence isn't sufficient, enterprise deals slow down. If pricing doesn't align with value, negotiations become harder.

The problem may look like execution.

But the root cause may be strategy.

This is why commercialization and go-to-market can't be separated. GTM executes the path to market. Commercialization determines whether that path makes sense in the first place.

Before accelerating the commercial engine, make sure the engine knows where it's going.

Early Traction Isn't the Same as Repeatability

Early traction matters.

A waitlist signals interest. A pilot creates learning. Letters of intent demonstrate potential demand. Early customers validate the problem. Founder-led sales can create important relationships and insight.

But early traction is evidence of possibility.

Scale requires evidence of repeatability.

Can the company consistently identify the right customers? Can it create demand beyond the founder's network? Can sales reproduce the same value conversation? Can customers move through implementation successfully? Can the company retain and expand them? Can it do all of that with economics that support growth?

Those are different questions.

The transition from early traction to scale happens when the company begins turning what it has learned into a commercial system.

Founder intuition becomes market intelligence.

Early wins reveal the ICP.

Successful conversations become positioning and sales enablement.

Customer outcomes become evidence.

Pricing becomes intentional.

Experiments become a repeatable go-to-market motion.

Scale begins when commercial success stops being episodic and starts becoming repeatable.

Commercialization Can't Wait Until the Product Is Ready

Perhaps the biggest mistake is thinking commercialization begins when it's time to sell.

By then, many of the decisions that shape commercial success have already been made.

Which problem the product solves. Which customers it serves. What evidence is generated. How the solution fits into existing workflows. How value will be measured. What business model supports it. Which markets are prioritized.

These are product decisions. They're also commercialization decisions.

That is why commercial capability needs to mature alongside innovation—not appear after it.

Women’s health has extraordinary market momentum. Capital is increasing. Innovation is accelerating. Categories are expanding. Buyers are paying attention.

The opportunity is increasingly clear.

The next challenge is building companies capable of capturing it.

Promising innovation doesn't become commercial scale simply because the opportunity exists. It scales when the commercial capabilities required to capture that opportunity mature alongside it.